Patents by Inventor Jordan S. Fridman

Jordan S. Fridman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES
    Publication number: 20200093825
    Abstract: Methods, kits, and compositions for treating dry eye disorders and other related eye diseases are provided, wherein the methods, kits, and compositions utilize a JAK inhibitor.
    Type: Application
    Filed: November 18, 2019
    Publication date: March 26, 2020
    Inventors: Paul A. Friedman, Jordan S. Fridman, Monica E. Luchi, William V. Williams
  • JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES
    Publication number: 20170087158
    Abstract: The present application relates to Janus kinase (JAK) inhibitors, including 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, for the treatment of a dry eye disorder or ameliorating a particular symptom of a dry eye disorder, such as eye discomfort, visual disturbance, tear film instability, tear hyperosmolarity, and inflammation of the ocular surface, as well as kits and compositions, including topical compositions, related thereto.
    Type: Application
    Filed: May 16, 2016
    Publication date: March 30, 2017
    Applicants: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Paul A. Friedman, Jordan S. Fridman, Monica E. Luchi, William V. Williams
  • Compositions, methods and kits relating to HER-2 cleavage
    Patent number: 9345677
    Abstract: The present invention relates to compositions, methods and kits based on the ADAM-mediated cleavage of Her-2. The present invention also relates to treatments for cancer, and in particular, breast cancer, by modulating the ADAM-mediated cleavage of Her-2. Further, the invention relates to compositions, methods and kits based on the surprising synergistic effect between inhibition of Her-2 cleavage by an ADAM and certain cytostatic (e.g., Herceptin) and cytotoxic (e.g., Taxol) compounds in, among other things, inhibiting tumor cell proliferation and inducing cell death. Additionally, the invention relates to novel variants of ADAM15, designated ADAM15 variant 1 and ADAM15 variant 2, now identified and isolated.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: May 24, 2016
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Steven M. Friedman, Peggy A. Scherle, Xiangdong Liu, Krishna Vaddi, Jordan S. Fridman
  • Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase
    Patent number: 9206187
    Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: December 8, 2015
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: James D. Rodgers, Stacey Shepard, Jordan S. Fridman, Krishna Vaddi
  • Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors
    Publication number: 20150238492
    Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Application
    Filed: May 13, 2015
    Publication date: August 27, 2015
    Inventors: James D. Rodgers, Stacey Shepard, Jordan S. Fridman, Krishna Vaddi
  • Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
    Patent number: 8946245
    Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: February 3, 2015
    Assignee: Incyte Corporation
    Inventors: James D. Rodgers, Stacey Shepard, Jordan S. Fridman, Krishna Vaddi
  • Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors
    Patent number: 8933086
    Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: January 13, 2015
    Assignee: Incyte Corporation
    Inventors: James D. Rodgers, Stacey Shepard, Jordan S. Fridman, Krishna Vaddi
  • AZEPINE INHIBITORS OF JANUS KINASES
    Publication number: 20140031344
    Abstract: The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Application
    Filed: September 20, 2013
    Publication date: January 30, 2014
    Applicant: INCYTE CORPORATION
    Inventors: Argyrios G. Arvanitis, James D. Rodgers, Andrew P. Combs, Richard B. Sparks, Darius J. Robinson, Jordan S. Fridman, Krishna Vaddi
  • Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors
    Publication number: 20140018374
    Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Application
    Filed: September 20, 2013
    Publication date: January 16, 2014
    Applicant: INCYTE CORPORATION
    Inventors: James D. Rodgers, Stacey Shepard, Jordan S. Fridman, Krishna Vaddi
  • Heteroaryl Substituted Pyrrolo[2,3-B] Pyridines And Pyrrolo[2,3-B] Pyrimidines As Janus Kinase Inhibitors
    Publication number: 20140005210
    Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Application
    Filed: September 6, 2013
    Publication date: January 2, 2014
    Applicant: Incyte Corporation
    Inventors: James D. Rodgers, Stacey Shepard, Thomas P. Maduskuie, JR., Haisheng Wang, Nikoo Falahatpisheh, Maria Rafalski, Argyrios G. Arvanitis, Louis Storace, Ravi Kumar Jalluri, Jordan S. Fridman, Krishna Vaddi
  • Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
    Patent number: 8541425
    Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Grant
    Filed: August 27, 2009
    Date of Patent: September 24, 2013
    Assignee: Incyte Corporation
    Inventors: James D. Rodgers, Stacey Shepard, Jordan S. Fridman, Krishna Vaddi
  • AZEPINE INHIBITORS OF JANUS KINASES
    Publication number: 20120329782
    Abstract: The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Application
    Filed: May 23, 2012
    Publication date: December 27, 2012
    Applicant: INCYTE CORPORATION
    Inventors: Argyrios G. Arvanitis, James D. Rodgers, Andrew P. Combs, Richard B. Sparks, Darius J. Robinson, Jordan S. Fridman, Krishna Vaddi
  • Combination therapy for the treatment of cancer
    Patent number: 8324194
    Abstract: The present invention provides methods of treating cancer comprising treating a patient in need thereof with hormone therapy and administering to the patient a therapeutically effective amount of at least one metalloprotease inhibitor. The present invention also provides pharmaceutical compositions comprising a therapeutically effective amount of at least one hormone therapy agent, at least one metalloprotease inhibitor, and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: November 21, 2006
    Date of Patent: December 4, 2012
    Assignee: Incyte Corporation
    Inventor: Jordan S. Fridman
  • JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES
    Publication number: 20120301464
    Abstract: Methods, kits, and compositions for treating dry eye disorders and other related eye diseases are provided, wherein the methods, kits, and compositions utilize a JAK inhibitor.
    Type: Application
    Filed: August 1, 2012
    Publication date: November 29, 2012
    Applicant: INCYTE CORPORATION
    Inventors: Paul A. Friedman, Jordan S. Fridman, Monica E. Luchi, William V. Williams
  • COMPOSITIONS, METHODS AND KITS RELATING TO HER-2 CLEAVAGE
    Publication number: 20120263676
    Abstract: The present invention relates to compositions, methods and kits based on the ADAM-mediated cleavage of Her-2. The present invention also relates to treatments for cancer, and in particular, breast cancer, by modulating the ADAM-mediated cleavage of Her-2. Further, the invention relates to compositions, methods and kits based on the surprising synergistic effect between inhibition of Her-2 cleavage by an ADAM and certain cytostatic (e.g., Herceptin) and cytotoxic (e.g., Taxol) compounds in, among other things, inhibiting tumor cell proliferation and inducing cell death. Additionally, the invention relates to novel variants of ADAM15, designated ADAM15 variant 1 and ADAM15 variant 2, now identified and isolated.
    Type: Application
    Filed: December 23, 2011
    Publication date: October 18, 2012
    Inventors: Steven M. Friedman, Peggy A. Scherle, Xiangdong Liu, Timothy C. Burn, Reid Huber, Phillip C.C. Liu, Gregory F. Hollis, Krishna Vaddi, Jordan S. Fridman
  • Compositions, methods and kits relating to Her-2 cleavage
    Patent number: 8088737
    Abstract: The present invention relates to compositions, methods and kits based on the ADAM-mediated cleavage of Her-2. The present invention also relates to treatments for cancer, and in particular, breast cancer, by modulating the ADAM-mediated cleavage of Her-2. Further, the invention relates to compositions, methods and kits based on the surprising synergistic effect between inhibition of Her-2 cleavage by an ADAM and certain cytostatic (e.g., Herceptin) and cytotoxic (e.g., Taxol) compounds in, among other things, inhibiting tumor cell proliferation and inducing cell death. Additionally, the invention relates to novel variants of ADAM15, designated ADAM15 variant 1 and ADAM15 variant 2, now identified and isolated.
    Type: Grant
    Filed: April 2, 2004
    Date of Patent: January 3, 2012
    Assignee: Incyte Corporation
    Inventors: Steven M. Friedman, Peggy A. Scherle, Xiangdong Liu, Timothy C. Burn, Reid Huber, Phillip C. C. Liu, Gregory F. Hollis, Krishna Vaddi, Jordan S. Fridman
  • HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
    Publication number: 20110224157
    Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Application
    Filed: March 30, 2011
    Publication date: September 15, 2011
    Inventors: James D. Rodgers, Stacey Shepard, Thomas P. Maduskuie, JR., Haisheng Wang, Nikoo Falahatpisheh, Maria Rafalski, Argyrios G. Arvanitis, Louis Storace, Ravi Kumar Jalluri, Jordan S. Fridman, Krishna Vaddi
  • HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
    Publication number: 20110223210
    Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Application
    Filed: March 30, 2011
    Publication date: September 15, 2011
    Inventors: James D. Rodgers, Stacey Shepard, Thomas P. Maduskuie, JR., Haisheng Wang, Nikoo Falahatpisheh, Maria Rafalski, Argyrios G. Arvanitis, Louis Storace, Ravikumar Jalluri, Jordan S. Fridman, Krishna Vaddi
  • JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES
    Publication number: 20100113416
    Abstract: Methods, kits, and compositions for treating dry eye disorders and other related eye diseases are provided, wherein the methods, kits, and compositions utilize a JAK inhibitor.
    Type: Application
    Filed: October 1, 2009
    Publication date: May 6, 2010
    Inventors: Paul A. Friedman, Jordan S. Fridman, Monica E. Luchi, William V. Williams
  • HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
    Publication number: 20100022522
    Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
    Type: Application
    Filed: August 27, 2009
    Publication date: January 28, 2010
    Inventors: James D. Rodgers, Stacey Shepard, Thomas P. Maduskuie, JR., Haisheng Wang, Nikoo Falahatpisheh, Maria Rafalski, Argyrios G. Arvanitis, Louis Storace, Ravikumar Jalluri, Jordan S. Fridman, Krishna Vaddi